Patents by Inventor Sanjeev Mariathasan

Sanjeev Mariathasan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220153861
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).
    Type: Application
    Filed: February 2, 2022
    Publication date: May 19, 2022
    Inventors: Richard BOURGON, David FABRIZIO, Gregg FINE, Garrett M. FRAMPTON, Priti HEGDE, Sanjeev MARIATHASAN, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY
  • Patent number: 11279767
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: March 22, 2022
    Assignees: Genentech, Inc., Foundation Medicine, Inc.
    Inventors: Richard Bourgon, David Fabrizio, Gregg Fine, Garrett M. Frampton, Priti Hegde, Sanjeev Mariathasan, Philip J. Stephens, James Xin Sun, Roman Yelensky
  • Publication number: 20210332143
    Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.
    Type: Application
    Filed: March 4, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Mahrukh Huseni, Joanna E. Klementowicz, Yijin Li, Li-Fen Liu, Sanjeev Mariathasan, Mark Merchant, Luciana Molinero, Lifen Wang, Nathaniel West, Patrick Williams, Chi Yung Yuen, Edward Namserk Cha, Yulei Wang
  • Publication number: 20210208143
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for bladder cancer (e.g., a locally advanced or metastatic urothelial carcinoma). The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient).
    Type: Application
    Filed: March 18, 2021
    Publication date: July 8, 2021
    Inventor: Sanjeev MARIATHASAN
  • Publication number: 20210032345
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: April 21, 2020
    Publication date: February 4, 2021
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Patent number: 10570192
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20200031936
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.
    Type: Application
    Filed: October 17, 2019
    Publication date: January 30, 2020
    Inventors: Priti HEGDE, Marcin KOWANETZ, Gregg FINE, Sanjeev MARIATHASAN, Richard BOURGON
  • Publication number: 20190309071
    Abstract: The present invention relates to the treatment of cancers, such as a prostate cancer (e.g., castration-resistant prostate cancer (CRPC)). More specifically, the invention concerns the treatment of human patients having a prostate cancer (e.g., CRPC, e.g., metastatic CRPC) with a combination therapy including an PD-1 axis binding antagonist and an antiandrogen.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 10, 2019
    Inventors: Sanjeev MARIATHASAN, Christina SCHIFF, Sujata NARAYANAN
  • Publication number: 20190085087
    Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.
    Type: Application
    Filed: November 15, 2018
    Publication date: March 21, 2019
    Inventors: Priti HEGDE, Luciana MOLINERO, Sanjeev MARIATHASAN, Shannon TURLEY, Jillian ASTARITA, Rafael CUBAS, Yagai YANG
  • Publication number: 20190016807
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: January 26, 2018
    Publication date: January 17, 2019
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Publication number: 20180371099
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).
    Type: Application
    Filed: August 28, 2018
    Publication date: December 27, 2018
    Inventors: Richard BOURGON, David FABRIZIO, Gregg FINE, Garrett M. FRAMPTON, Priti HEGDE, Sanjeev MARIATHASAN, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY
  • Publication number: 20180292391
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: February 20, 2018
    Publication date: October 11, 2018
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Publication number: 20180125995
    Abstract: The invention provides rF1 antibody antibiotic conjugates and methods of using same.
    Type: Application
    Filed: June 2, 2017
    Publication date: May 10, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric Brown, Wouter Hazenbos, Isidro Hotzel, Kimberly Kajihara, Sophie M. Lehar, Sanjeev Mariathasan, Thomas Pillow, Leanna Staben, Vishal Verma, Binqing Wei, Yi Xia, Min Xu
  • Publication number: 20180085470
    Abstract: The invention provides anti-wall teichoic acid antibodies, antibiotic-linker intermediates, and antibody-antibiotic conjugate compound, and methods of making and using the same.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9927428
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 27, 2018
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Patent number: 9920123
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • Patent number: 9895450
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20180037655
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.
    Type: Application
    Filed: October 23, 2017
    Publication date: February 8, 2018
    Inventors: Priti HEGDE, Marcin KOWANETZ, Gregg FINE, Sanjeev MARIATHASAN, Richard BOURGON
  • Patent number: 9884126
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20180021450
    Abstract: The invention provides anti-Staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.
    Type: Application
    Filed: June 2, 2017
    Publication date: January 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric Brown, Wouter Hazenbos, Isidro Hotzel, Kimberly Kajihara, Sophie M. Lehar, Sanjeev Mariathasan, Thomas Pillow, Leanna Staben, Vishal Verma, Binqing Wei, Min Xu